Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy
Reference4 articles.
1. Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372–385 (2019). A review article discussing lessons learned from the clinical use of CD19 CAR-T therapy, including CAR-T treatment mechanisms.
2. Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282–1295 (2015). This seminal study describes CD19 genomic locus mutations and alternative splicing events that lead to CD19 CAR-T resistance.
3. Zhao, Y. et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood 137, 471–484 (2021). Extensive characterization of blinatumomab therapy in patients with primary B-ALL, including extensive kinetic analysis of treatment responses and relapse.
4. Kozmik, Z., Wang, S., Dorfler, P., Adams, B. & Busslinger, M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol. Cell Biol. 12, 2662–2672 (1992). Original study highlighting the role of PAX5 (also known as BSAP) in activating CD19 mRNA expression via promoter binding.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献